相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function Insights From EMPEROR-Reduced
Faiez Zannad et al.
CIRCULATION (2021)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF
Pardeep S. Jhund et al.
CIRCULATION (2021)
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
Matthew R. Weir et al.
CLINICAL KIDNEY JOURNAL (2021)
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial
Stefan D. Anker et al.
CIRCULATION (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
Bettina J. Kraus et al.
KIDNEY INTERNATIONAL (2021)
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
Jesper Jensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists An Analysis of DAPA-HF
Li Shen et al.
JACC-HEART FAILURE (2021)
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Joao Pedro Ferreira et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Milton Packer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
Jiali Liu et al.
DIABETES OBESITY & METABOLISM (2020)
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Kieran F. Docherty et al.
EUROPEAN HEART JOURNAL (2020)
The tubular hypothesis of nephron filtration and diabetic kidney disease
Volker Vallon et al.
NATURE REVIEWS NEPHROLOGY (2020)
We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury
Vikas S. Sridhar et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Francesco Cosentino et al.
CIRCULATION (2020)
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy
Kieran F. Docherty et al.
DIABETES CARE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Chiara Maria Assunta Cefalo et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program
Gemma A. Figtree et al.
CIRCULATION (2019)
Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors A Review of Spontaneous Postmarketing Cases
Susan J. Bersoff-Matcha et al.
ANNALS OF INTERNAL MEDICINE (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Andrew A. House et al.
KIDNEY INTERNATIONAL (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus
T. Cooper Woods et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
Concetta Irace et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment
Ichiro Horie et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2018)
Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect
Philipp F. Secker et al.
CELL DEATH & DISEASE (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
Debapriya Basu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington et al.
CLINICAL KIDNEY JOURNAL (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Satish K. Garg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Proposal of a Novel Mechanism of Action
Milton Packer et al.
JAMA CARDIOLOGY (2017)
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ele Ferrannini
CELL METABOLISM (2017)
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Christian Ott et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Progression after AKI: Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments
David P. Basile et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
Panai Song et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
Management of patients with diabetes and CKD: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Vlado Perkovic et al.
KIDNEY INTERNATIONAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
William G. Herrington et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus
Biff F. Palmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
Meyeon Park et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
A Study of Orthoglycaemic Glycosuria with Particular Reference to its Hereditability.
URBAN HJÄRNE.
ACTA MEDICA SCANDINAVICA (2010)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
分享论文
